
Mexico’s Social Security Agency Sues Israel’s Teva for Allegedly Bribing Doctors
Israeli pharmaceutical giant accused of earning $18.6 million through bribes to doctors at hospitals owned by Mexican Social Security Institute
Israeli pharmaceutical giant accused of earning $18.6 million through bribes to doctors at hospitals owned by Mexican Social Security Institute
Israeli drug manufacturer’s many legal entanglements may cost it even more than previously forecast – and twice what the company itself has set aside, rating agency says
The pharmaceutical giant is charged with conspiring with competitors to raise prices, could face $100 million fine
In yet another lawsuit exposing its American activities, Israeli drugmaker is accused of using charities to deflect attention from soaring price for MS drug Copaxone
Patients stocking up on drugs lifted sales in the first quarter. The current quarter may be weaker, but Israeli drugmaker remains bullish for the year
Company sees strong growth in migraine treatment Ajovy and Huntington’s treatment Austedo in 2020
An advantageous deal to get itself out of the opioid scandal brought investors back – but the storm is gaining strength again
Shares of Israel's Teva, other drug companies drop after grand-jury subpoenas from the U.S. attorney’s office in the Eastern District of New York
The New York State Department of Financial Services has sent letters to around 23 opioid manufacturers and distributors
A drop in profit was expected, but despite the optimism, Teva is nowhere near out of the opioid scandal
Company announced value of donated medicine based on list price, which does not account for routine, significant discounts
Tentative $23 billion deal announced on Monday could be boost for financially troubled Israeli drug maker. But deal remains short on details, and not all the plaintiffs may sign on
Last-minute $260 million legal settlement averts first federal trial over companies' role in opioid addiction epidemic
While Tate museums and Guggenheim cut ties with the family, the Smithsonian, Metropolitan Museum of Art and Harvard are struggling due to contractual obligations
Israeli drug company sank 9.6% on Nasdaq on Tuesday
In first case to go to trial out of thousands of lawsuits, payment ordered by an Oklahoma judge is 'much lower than had been feared,' says healthcare strategist
Moody's puts Negative outlook on drug makers debt ■ Stock drops to 10.51 % at $6.30
Israeli drug giant's shares dropped more than 13% on the Tel Aviv Stock Exchange the same day the company's chief financial officer announced his resignation
Payment is to cover part of penalties drug maker paid to U.S., Israel
Troubling disclosures likely to pressure pharmaceutical companies to settle suits quickly, a development Israel’s Teva will try to avoid
Yields have risen sharply, complicating drug maker’s plans to recycle debt
Analyst David Risinger of Morgan Stanley lowered his future price for the stock on the Nasdaq from $16 to $6; it closed in Tel Aviv Monday at $8.49
Deal came just days before the drugmaker was set to face trial for its alleged role in helping to fuel epidemic
Investors fear the drugmaker will pay billions for its alleged role in the U.S. opioid epidemic, while the communications giant has been stung by losses at its satellite TV unit
Settlement reached days before company was set to face trial
Legendary investor had 3.9% stake in drug marker at end of first quarter
The drug maker not only faces price-fixing allegations in the U.S. but also is a party to a suit on opiod abuse
Israeli institutional investors seeking class action in the U.S. estimate that price-fixing inflated Teva's profits by $2.3 billion
It’s a nasty business but the financial impact on Teva is containable and the bigger picture for the troubled drug maker is looking brighter
'We all wonder why the prices for generic prescription drugs are so expensive – this is a big reason why,' Connecticut attorney general says, alleging price-fixing conspiracy